Cargando…

Semi-Automated Glycoproteomic Data Analysis of LC-MS Data Using GlycopeptideGraphMS in Process Development of Monoclonal Antibody Biologics

The glycosylation of antibody-based proteins is vital in translating the right therapeutic outcomes of the patient. Despite this, significant infrastructure is required to analyse biologic glycosylation in various unit operations from biologic development, process development to QA/QC in bio-manufac...

Descripción completa

Detalles Bibliográficos
Autores principales: Pang, Kuin Tian, Tay, Shi Jie, Wan, Corrine, Walsh, Ian, Choo, Matthew S. F., Yang, Yuan Sheng, Choo, Andre, Ho, Ying Swan, Nguyen-Khuong, Terry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167043/
https://www.ncbi.nlm.nih.gov/pubmed/34084765
http://dx.doi.org/10.3389/fchem.2021.661406
_version_ 1783701612842188800
author Pang, Kuin Tian
Tay, Shi Jie
Wan, Corrine
Walsh, Ian
Choo, Matthew S. F.
Yang, Yuan Sheng
Choo, Andre
Ho, Ying Swan
Nguyen-Khuong, Terry
author_facet Pang, Kuin Tian
Tay, Shi Jie
Wan, Corrine
Walsh, Ian
Choo, Matthew S. F.
Yang, Yuan Sheng
Choo, Andre
Ho, Ying Swan
Nguyen-Khuong, Terry
author_sort Pang, Kuin Tian
collection PubMed
description The glycosylation of antibody-based proteins is vital in translating the right therapeutic outcomes of the patient. Despite this, significant infrastructure is required to analyse biologic glycosylation in various unit operations from biologic development, process development to QA/QC in bio-manufacturing. Simplified mass spectrometers offer ease of operation as well as the portability of method development across various operations. Furthermore, data analysis would need to have a degree of automation to relay information back to the manufacturing line. We set out to investigate the applicability of using a semiautomated data analysis workflow to investigate glycosylation in different biologic development test cases. The workflow involves data acquisition using a BioAccord LC-MS system with a data-analytical tool called GlycopeptideGraphMS along with Progenesis QI to semi-automate glycoproteomic characterisation and quantitation with a LC-MS1 dataset of a glycopeptides and peptides. Data analysis which involved identifying glycopeptides and their quantitative glycosylation was performed in 30 min with minimal user intervention. To demonstrate the effectiveness of the antibody and biologic glycopeptide assignment in various scenarios akin to biologic development activities, we demonstrate the effectiveness in the filtering of IgG1 and IgG2 subclasses from human serum IgG as well as innovator drugs trastuzumab and adalimumab and glycoforms by virtue of their glycosylation pattern. We demonstrate a high correlation between conventional released glycan analysis with fluorescent tagging and glycopeptide assignment derived from GraphMS. GraphMS workflow was then used to monitor the glycoform of our in-house trastuzumab biosimilar produced in fed-batch cultures. The demonstrated utility of GraphMS to semi-automate quantitation and qualitative identification of glycopeptides proves to be an easy data analysis method that can complement emerging multi-attribute monitoring (MAM) analytical toolsets in bioprocess environments.
format Online
Article
Text
id pubmed-8167043
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81670432021-06-02 Semi-Automated Glycoproteomic Data Analysis of LC-MS Data Using GlycopeptideGraphMS in Process Development of Monoclonal Antibody Biologics Pang, Kuin Tian Tay, Shi Jie Wan, Corrine Walsh, Ian Choo, Matthew S. F. Yang, Yuan Sheng Choo, Andre Ho, Ying Swan Nguyen-Khuong, Terry Front Chem Chemistry The glycosylation of antibody-based proteins is vital in translating the right therapeutic outcomes of the patient. Despite this, significant infrastructure is required to analyse biologic glycosylation in various unit operations from biologic development, process development to QA/QC in bio-manufacturing. Simplified mass spectrometers offer ease of operation as well as the portability of method development across various operations. Furthermore, data analysis would need to have a degree of automation to relay information back to the manufacturing line. We set out to investigate the applicability of using a semiautomated data analysis workflow to investigate glycosylation in different biologic development test cases. The workflow involves data acquisition using a BioAccord LC-MS system with a data-analytical tool called GlycopeptideGraphMS along with Progenesis QI to semi-automate glycoproteomic characterisation and quantitation with a LC-MS1 dataset of a glycopeptides and peptides. Data analysis which involved identifying glycopeptides and their quantitative glycosylation was performed in 30 min with minimal user intervention. To demonstrate the effectiveness of the antibody and biologic glycopeptide assignment in various scenarios akin to biologic development activities, we demonstrate the effectiveness in the filtering of IgG1 and IgG2 subclasses from human serum IgG as well as innovator drugs trastuzumab and adalimumab and glycoforms by virtue of their glycosylation pattern. We demonstrate a high correlation between conventional released glycan analysis with fluorescent tagging and glycopeptide assignment derived from GraphMS. GraphMS workflow was then used to monitor the glycoform of our in-house trastuzumab biosimilar produced in fed-batch cultures. The demonstrated utility of GraphMS to semi-automate quantitation and qualitative identification of glycopeptides proves to be an easy data analysis method that can complement emerging multi-attribute monitoring (MAM) analytical toolsets in bioprocess environments. Frontiers Media S.A. 2021-05-18 /pmc/articles/PMC8167043/ /pubmed/34084765 http://dx.doi.org/10.3389/fchem.2021.661406 Text en Copyright © 2021 Pang, Tay, Wan, Walsh, Choo, Yang, Choo, Ho and Nguyen-Khuong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Chemistry
Pang, Kuin Tian
Tay, Shi Jie
Wan, Corrine
Walsh, Ian
Choo, Matthew S. F.
Yang, Yuan Sheng
Choo, Andre
Ho, Ying Swan
Nguyen-Khuong, Terry
Semi-Automated Glycoproteomic Data Analysis of LC-MS Data Using GlycopeptideGraphMS in Process Development of Monoclonal Antibody Biologics
title Semi-Automated Glycoproteomic Data Analysis of LC-MS Data Using GlycopeptideGraphMS in Process Development of Monoclonal Antibody Biologics
title_full Semi-Automated Glycoproteomic Data Analysis of LC-MS Data Using GlycopeptideGraphMS in Process Development of Monoclonal Antibody Biologics
title_fullStr Semi-Automated Glycoproteomic Data Analysis of LC-MS Data Using GlycopeptideGraphMS in Process Development of Monoclonal Antibody Biologics
title_full_unstemmed Semi-Automated Glycoproteomic Data Analysis of LC-MS Data Using GlycopeptideGraphMS in Process Development of Monoclonal Antibody Biologics
title_short Semi-Automated Glycoproteomic Data Analysis of LC-MS Data Using GlycopeptideGraphMS in Process Development of Monoclonal Antibody Biologics
title_sort semi-automated glycoproteomic data analysis of lc-ms data using glycopeptidegraphms in process development of monoclonal antibody biologics
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167043/
https://www.ncbi.nlm.nih.gov/pubmed/34084765
http://dx.doi.org/10.3389/fchem.2021.661406
work_keys_str_mv AT pangkuintian semiautomatedglycoproteomicdataanalysisoflcmsdatausingglycopeptidegraphmsinprocessdevelopmentofmonoclonalantibodybiologics
AT tayshijie semiautomatedglycoproteomicdataanalysisoflcmsdatausingglycopeptidegraphmsinprocessdevelopmentofmonoclonalantibodybiologics
AT wancorrine semiautomatedglycoproteomicdataanalysisoflcmsdatausingglycopeptidegraphmsinprocessdevelopmentofmonoclonalantibodybiologics
AT walshian semiautomatedglycoproteomicdataanalysisoflcmsdatausingglycopeptidegraphmsinprocessdevelopmentofmonoclonalantibodybiologics
AT choomatthewsf semiautomatedglycoproteomicdataanalysisoflcmsdatausingglycopeptidegraphmsinprocessdevelopmentofmonoclonalantibodybiologics
AT yangyuansheng semiautomatedglycoproteomicdataanalysisoflcmsdatausingglycopeptidegraphmsinprocessdevelopmentofmonoclonalantibodybiologics
AT chooandre semiautomatedglycoproteomicdataanalysisoflcmsdatausingglycopeptidegraphmsinprocessdevelopmentofmonoclonalantibodybiologics
AT hoyingswan semiautomatedglycoproteomicdataanalysisoflcmsdatausingglycopeptidegraphmsinprocessdevelopmentofmonoclonalantibodybiologics
AT nguyenkhuongterry semiautomatedglycoproteomicdataanalysisoflcmsdatausingglycopeptidegraphmsinprocessdevelopmentofmonoclonalantibodybiologics